Multigene Methylation Changes and Treatment Response in Gastric Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study examines if shifts in circulating methylation patterns of multiple genes, measured before and after treatment, correlate with response rates seen on CT/MRI and with tumor marker levels. It also explores whether these methylation changes relate to progression-free survival over time and if methylation data can outperform conventional biomarkers in diagnosing or guiding therapy decisions. The goal is to see if methylation thresholds could support adaptive treatment modifications. Participants are adults with newly diagnosed gastric or gastroesophageal junction cancer who have not yet received systemic therapy and meet safety criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Age at initial diagnosis: 18-75 years Histologically confirmed gastric or gastroesophageal junction malignancy, with complete medical records, confirmed pathological diagnosis, and definitive staging data (TNM staging system) No history of other primary malignancies Absence of distant metastases (liver, lung, or other sites) confirmed by imaging examination (CT/MRI) No prior surgical resection, chemotherapy, or PD-1/PD-L1 immunotherapy before enrollment Availability of complete biospecimen information, including: Sample ID (medical record number), Demographic data (sex, age), Clinical diagnostic data, Tumor marker profiles (CEA, CA19-9, etc.)

Exclusion Criteria:

Life expectancy \<6 months (as assessed by ECOG score ≥4 or Palliative Performance Scale ≤30%) Cognitive/psychiatric conditions: a. Legally incapacitated individuals without legal guardians, b. Active psychotic disorders (e.g., schizophrenia, bipolar disorder) or dementia (MMSE score \<24) Investigator-determined exclusions

Where it's running

• Tangdu Hospital
  Xi'an, Shaanxi, China Recruiting
• Xijing Hospital
  Xi'an, Shaanxi, China Recruiting

Study contacts

• Study coordinator: Zhongyang Zhang
• Email: 18831363219@163.com
• Phone: +86 188 3136 3219

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers

  This study tests whether clonal hematopoiesis affects outcomes for adults with solid cancers who are receiving chemotherapy or radiation.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07675967

• BHB810 in advanced gastric and GEJ cancer (early-phase)

  This study tests whether BHB810 can be safely given every two weeks to adults with advanced gastric or GEJ adenocarcinoma and looks at its effect, how the drug behaves in the body, and patient responses.

  Recruiting at 2 sites Phase 1/2 BigHat Biosciences, Inc. · Duarte, California and 2 other locations · NCT07529808

• First-in-human dose study of DA-3501 for CLDN18.2-positive stomach, GEJ cancer, and pancreatic cancer

  A first-in-human study tests DA-3501 in adults with CLDN18.2-positive advanced stomach/GEJ cancer or pancreatic cancer to find a safe, effective dose.

  Recruiting at 3 sites Phase 1 Dong-A ST Co., Ltd. · Seongnam, Bundang and 2 other locations · NCT07481357

• Gastric cancer characteristics and care patterns in Algeria

  This project collects medical records and short interviews to describe who has gastric cancer and how they are diagnosed and treated at Algerian oncology centers.

  Recruiting Société Algérienne de Formation et Recherche en Oncologie · Algiers, Algeria and 14 other locations · NCT07481110

• Riluzole to prevent thinking and memory problems during chemotherapy

  This pilot trial tests whether riluzole can prevent thinking and memory problems in adults with cancer receiving anthracycline- or platinum-based chemotherapy.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT07447050

• TCC1727 combined with other cancer medicines for adults with advanced solid tumors

  This phase Ib/II trial tests TCC1727 given with benmelstobart, olaparib, or topotecan in adults with advanced solid tumors to find safe doses and see if the combinations help control tumors.

  Recruiting Phase 1/2 Beijing Tide Pharmaceutical Co., Ltd · Beijing, Beijing Municipality and 2 other locations · NCT07371663

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.